SynthesisCancer reports (Hoboken, N.J.)2026
An In-Depth Evaluation of CD15 Expression in Thyroid Carcinoma: A Comprehensive Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of CD10 Expression in Endometrial Carcinoma: A Systematic Review.Iranian journal of pathology · 2026Review
- ERK Signaling in Thyroid Cancer: Lineage Suppression, Epigenetic Reprogramming, and Theranostic Reversal.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCluster of differentiation 15 (CD15) is a carbohydrate epitope implicated in cell adhesion, migration, and tumor progression. It is variably expressed in thyroid carcinoma (TC) subtypes. However, its diagnostic and prognostic value remains uncertain due to methodological heterogeneity and inconsistent findings.
aimTo systematically review the prevalence, clinicopathologic associations, and diagnostic utility of CD15 expression across TC subtypes. METHODS AND
resultsFollowing PRISMA guidelines, a systematic search was conducted in May 2025 across PubMed, Scopus, and Web of Science. Sixteen observational studies evaluating CD15 expression in human TC were included. Risk of bias was assessed using the ROBINS-I tool. A total of 1665 TC cases were analyzed. Classic papillary thyroid carcinoma (CPTC) showed moderate overall prevalence (0%-100%), follicular variant papillary thyroid carcinoma (FVPTC) demonstrated lower expression (17.6%-80%), while tall-cell papillary thyroid carcinoma (TCPTC) exhibited the highest positivity (71%-100%). Follicular thyroid carcinoma (FTC) showed modest expression, whereas medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) demonstrated overall low positivity. CD15 showed high specificity (90%-100%) for PTC, but sensitivity was inconsistent, particularly in follicular variants.
conclusionCD15 demonstrates high specificity for PTC. However, its limited sensitivity and variable expression in follicular-patterned lesions make its prognostic value unclear. CD15 should not be used as a standalone marker; instead, it may improve diagnostic accuracy when combined with other markers in multiparametric immunohistochemical panels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.